Markets & Investing
Why Alts.Co Invested in the Psychedelics Industry (LIVE EVENT)
Nucleus CEO, Logan Lenz, sits down with Stefan von Imhof, the CEO of Alts.co to discuss Nucleus and the massive opportunity for the psychedelics industry…

Nucleus CEO, Logan Lenz, sits down with Stefan von Imhof, the CEO of Alts.co to discuss Nucleus and the massive opportunity for the psychedelics industry in the coming years.
A few months back, Alts published a deep dive on Nucleus, a venture studio for psychedelics (and Psychedelic Invest’s parent company).
Stefan is the co-founder and CEO of Alts.co. He’s a huge fan of alternative investing and has a strong background in alternative asset analysis and valuations. Prior to co-founding Alts.co, Stefan was Head of Product at Flippa where he created Flippa’s Due Diligence Program, He also spent time at Citrix and lynda.com, which was bought by LinkedIn, and was the first product manager at HG Insights, a market intelligence company that sold to Riverwood Capital Partners in 2020. Originally from Boston and later Santa Barbara, CA, he now lives in Australia with his wife & Boston Terrier, Charlie.
More About Alts.co
Alts.co provides original research and insights you can trust on alternative assets. Over 85,000 subscribers are delivered investment opportunities and insights straight to their inbox.
Investing in Nucleus
For those who don’t know by now, Nucleus currently allows anyone to invest in the company with as little as $200. All you must do is visit the Wefunder page, select your investment amount, and go through Wefunder’s transaction process.
Stay tuned for more Nucleus events and webinars as the campaign continues.
RSVP To Reserve Your Spot

-
Psilocybin8 hours ago
Are Psychedelics a New Paradigm or Business as Usual?
-
Psilocybin8 hours ago
Lucy Scientific Acquires Psychedelic Assets from Wesana Health
-
Psilocybin12 hours ago
Microsoft brings OpenAI’s DALL-E image creator to the new Bing
-
DMT6 hours ago
New Study Gives Most Advanced View of the Brain on Psychedelics
-
Markets & Investing6 hours ago
Tom McDonald, CEO of Clerkenwell Health, Sits in the Investor Hotseat on March 30th
-
Psilocybin6 hours ago
First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder